drugset / Trial / NCT00363974
Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the drug, called AEG35156, can be safely given to AML patients and whether it effectively reduces levels of a protein (XIAP) to increase the sensitivity of cancer cells to chemotherapy (ara-C and idarubicin) in patients with refractory or relapsed AML.
Timeline
- Start
- 2005-10
- Primary completion
- 2009-03
- Completion
- 2009-03
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AEG35156 | Antisense oligonucleotide | 12 mg/m2 | — |
| Subject | AEG35156 | Antisense oligonucleotide | 24 mg/m2 | — |
| Subject | AEG35156 | Antisense oligonucleotide | 48 mg/m2 | — |
| Subject | AEG35156 | Antisense oligonucleotide | 75 mg/m2 | — |
| Subject | AEG35156 | Antisense oligonucleotide | 110 mg/m2 | — |
| Subject | AEG35156 | Antisense oligonucleotide | 165 mg/m2 | — |
| Subject | AEG35156 | Antisense oligonucleotide | 250 mg/m2 | — |
| Subject | AEG35156 | Antisense oligonucleotide | 350 mg/m2 | — |